Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 707-717

  Henken, Stefanie ^a   Bohling, Jennifer ^a   Martens Lobenhoffer, Jens ^b   Paton, James C ^c   Ogunniyi, A David ^c   Briles, David E ^d   Salisbury, Vyvyan C ^e   Wedekind, Dirk ^a   Bode Böger, Stefanie M ^b   Welsh, Thomas ^f   Bange, Franz C ^a   Welte, Tobias ^a   Maus, Ulrich A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^f NOVARTIS PHARMA GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; DAPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOLUMINESCENCE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; EXPERIMENTAL MOUSE; LUNG INFECTION; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEPSIS; SEPTIC PNEUMOCOCCAL DISEASE; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; DAPTOMYCIN; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; SEPSIS; STREPTOCOCCUS PNEUMONIAE;

EID: 75749155809     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00943-09     Document Type: Article

References (36)

1. Akins, R. L., and K. K. Haase. 2005. Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 25:1001-1010.
2. Alloush, H. M., V. Salisbury, R. J. Lewis, and A. P. MacGowan. 2003. Pharmacodynamics of linezolid in a clinical isolate of Streptococcus pneumoniae genetically modified to express lux genes. J. Antimicrob. Chemother. 52:511-513.
3. Baltz, R. H. 2009. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr. Opin. Chem. Biol. 13:144-151.
4. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.
5. Beard, S. J., V. Salisbury, R. J. Lewis, J. A. Sharpe, and A. P. MacGowan. 2002. Expression of lux genes in a clinical isolate of Streptococcus pneumoniae: using bioluminescence to monitor gemifloxacin activity. Antimicrob. Agents Chemother. 46:538-542.
6. Briles, D. E., S. K. Hollingshead, J. C. Paton, E. W. Ades, L. Novak, F. W. van Ginkel, and W. H. Benjamin, Jr. 2003. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J. Infect. Dis. 188:339-348.
7. Cottagnoud, P., M. Pfister, F. Acosta, M. Cottagnoud, L. Flatz, F. Kuhn, H. P. Muller, and A. Stucki. 2004. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. 48:3928-3933.
8. Del Maschio, A., A. De Luigi, I. Martin-Padura, M. Brockhaus, T. Bartfai, P. Fruscella, L. Adorini, G. Martino, R. Furlan, M. G. De Simoni, and E. Dejana. 1999. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J. Exp. Med. 190:1351-1356.
9. Felmingham, D., R. Canton, and S. G. Jenkins. 2007. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J. Infect. 55:111-118.
10. Hair, P. I., and S. J. Keam. 2007. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteremia. Drugs 67:1483-1512.
11. Jorgensen, J. H., and S. A. Crawford. 2006. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J. Clin. Microbiol. 44:2126-2129.
12. Kadioglu, A., and P. W. Andrew. 2004. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol. 25:143-149.
13. Karlstrom, A., K. L. Boyd, B. K. English, and J. A. McCullers. 2009. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J. Infect. Dis. 199:311-319.
14. Mahdi, L. K., A. D. Ogunniyi, K. S. LeMessurier, and J. C. Paton. 2008. Pneumococcal virulence gene expression and host cytokine profiles during pathogenesis of invasive disease. Infect. Immun. 76:646-657.
15. Martens-Lobenhoffer, J., J. T. Kielstein, C. Oye, and S. M. Bode-Boger. 2008. Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 875:546-550.
16. Maus, U., J. Huwe, R. Maus, W. Seeger, and J. Lohmeyer. 2001. Alveolar JE/MCP-1 and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte influx, and vascular leakage in mice. Am. J. Respir. Crit. Care Med. 164:406-411.
17. Maus, U., K. von Grote, W. A. Kuziel, M. Mack, E. J. Miller, J. Cihak, M. Stangassinger, R. Maus, D. Schlondorff, W. Seeger, and J. Lohmeyer. 2002. The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Am. J. Respir. Crit. Care Med. 166:268-273.
18. Maus, U. A., M. Backi, C. Winter, M. Srivastava, M. K. Schwarz, T. Ruckle, J. C. Paton, D. Briles, M. Mack, T. Welte, R. Maus, R. M. Bohle, W. Seeger, C. Rommel, E. Hirsch, J. Lohmeyer, and K. T. Preissner. 2007. Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am. J. Respir. Crit. Care Med. 175:958-966.
19. Maus, U. A., M. A. Koay, T. Delbeck, M. Mack, M. Ermert, L. Ermert, T. S. Blackwell, J. W. Christman, D. Schlondorff, W. Seeger, and J. Lohmeyer. 2002. Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 282:L1245-L1252.
20. Maus, U. A., K. Waelsch, W. A. Kuziel, T. Delbeck, M. Mack, T. S. Blackwell, J. W. Christman, D. Schlondorff, W. Seeger, and J. Lohmeyer. 2003. Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis. J. Immunol. 170:3273- 3278.
21. Miao, V., M. F. Coeffet-Legal, P. Brian, R. Brost, J. Penn, A. Whiting, S. Martin, R. Ford, I. Parr, M. Bouchard, C. J. Silva, S. K. Wrigley, and R. H. Baltz. 2005. Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 151:1507-1523.
22. Orihuela, C. J., G. Gao, M. McGee, J. Yu, K. P. Francis, and E. Tuomanen. 2003. Organ-specific models of Streptococcus pneumoniae disease. Scand. J. Infect. Dis. 35:647-652.
23. Pertel, P. E., P. Bernardo, C. Fogarty, P. Matthews, R. Northland, M. Benvenuto, G. M. Thorne, S. A. Luperchio, R. D. Arbeit, and J. Alder. 2008. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin. Infect. Dis. 46:1142-1151.
24. Reinert, R. R. 2009. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin. Microbiol. Infect. 15(Suppl. 3):7-11.
25. Sauermann, R., M. Rothenburger, W. Graninger, and C. Joukhadar. 2008. Daptomycin: a review 4 years after first approval. Pharmacology 81:79-91.
26. Silverman, J. A., L. I. Mortin, A. D. Vanpraagh, T. Li, and J. Alder. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191:2149-2152.
27. Silverman, J. A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.
28. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
29. Steenbergen, J. N., J. Alder, G. M. Thorne, and F. P. Tally. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55:283-288.
30. Tally, F. P., and M. F. DeBruin. 2000. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46:523-526.
31. Tally, F. P., M. Zeckel, M. M. Wasilewski, C. Carini, C. L. Berman, G. L. Drusano, and F. B. Oleson, Jr. 1999. Daptomycin: a novel agent for Grampositive infections. Expert Opin. Investig. Drugs 8:1223-1238.
32. Thallinger, C., M. Rothenburger, C. Marsik, S. Wuenscher, M. Popovic, G. Endler, O. Wagner, and C. Joukhadar. 2008. Daptomycin does not exert immunomodulatory effects in an experimental endotoxin model of human whole blood. Pharmacology 81:57-62.
33. WHO. 2007. Pneumococcal conjugate vaccine for childhood immunization. WHO position paper. Wkly. Epidemiol. Rec. 82:93-104.
34. Winter, C., W. Herbold, R. Maus, F. Langer, D. E. Briles, J. C. Paton, T. Welte, and U. A. Maus. 2009. Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J. Immunol. 182:4931-4937.
35. Winter, C., K. Taut, F. Langer, M. Mack, D. E. Briles, J. C. Paton, R. Maus, M. Srivastava, T. Welte, and U. A. Maus. 2007. FMS-like tyrosine kinase 3 ligand aggravates the lung inflammatory response to Streptococcus pneumoniae infection in mice: role of dendritic cells. J. Immunol. 179:3099-3108.
36. Winter, C., K. Taut, M. Srivastava, F. Langer, M. Mack, D. E. Briles, J. C. Paton, R. Maus, T. Welte, M. D. Gunn, and U. A. Maus. 2007. Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. J. Immunol. 178:5828-5838.